The company intends to utilise the funds to support the development of world’s smallest microarray of sensors for continuous glucose monitoring
Medical device company Biolinq has secured a $100m in Series B financing for its micro-array of biosensors designed for continuous glucose monitoring.
Biolinq is involved in the development of a wearable biosensor platform to measure biomarkers for the management of multiple clinical conditions, including diabetes.
Led by RiverVest Venture Partners, the Series B financing round witnessed participation from T&W Medical, AXA IM Alts, Global Health Investment, Ascensia Diabetes Care, Longevity Vision Fund, Falcon Edge Capital, Aphelion Capital, M Ventures, and Hikma Ventures, among others.